Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings Sprint Bioscience AB: Strengths and Weaknesses

Highlights: Sprint Bioscience AB
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Sprint Bioscience AB
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Rating Financials

Sprint Bioscience AB SectorSweden

Fundamentals

-

Growth

-

Revenue growth

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Sprint Bioscience AB SectorSweden

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Sprint Bioscience AB SectorSweden

Consensus

-

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

-

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sprint Bioscience AB SectorSweden

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Sprint Bioscience AB SectorSweden

Financial revisions

-

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

-

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
35.94M - - - - - - -
74.46B
AAA
60.14B
A
48.15B
AAA
44.25B
AAA
43.99B -
B
- -
41.61B -
29.97B
A
29.31B
AAA
24.93B -
BBB
- -
Average 39.68B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. SPRINT Stock
  4. Ratings Sprint Bioscience AB